Denied Osteoporosis Drug Appeals: Reviewer Outcomes

A physician-administered agent for osteoporosis given by injection or infusion and billed under the medical benefit with its own supply code.

What the independent reviewers decided

67%

overturned by the independent reviewer

of 55 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny osteoporosis infusion

The policy requires a documented trial of an oral bisphosphonate and the record does not evidence it.
The bone-density result the policy requires is absent or outside the interval it accepts.
The fracture history the policy relies on is not documented.
Continuation is denied because a follow-up density study is not on file.

What actually carried the cases that won

Prior treatment led in 95% of the overturned decisions, and FDA labelling was the authority reviewers relied on most here — the only procedure group where labelling came first. The reading is straightforward: evidence the oral trial as a trial (agent, dose, duration, why it stopped, with intolerance distinguished from failure), and locate the request inside a labelled indication.

What the record showed	Share of overturned decisions
Prior treatment was documented	95%
A published guideline supported the request	54%
The condition was documented as chronic or long-standing	38%
The severity or urgency was documented	27%
The diagnosis was confirmed	27%
Objective findings were documented	19%
The functional impact on the patient was documented	16%
Conservative treatment was documented as failed	11%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

FDA labeling — in 35% of the overturned decisions
Peer-reviewed literature — in 27% of the overturned decisions
Clinical guidelines — in 16% of the overturned decisions
Specialty-society criteria — in 8% of the overturned decisions

osteoporosis infusion denials — frequently asked

Is a denied osteoporosis infusion worth appealing?

67% of 55 California independent medical reviews were overturned — two in three on a modest sample.

What counts as an adequate oral trial?

What the policy says, in its terms — and crucially, an intolerance is not a failure. Records that documented a specific adverse effect and its date fared differently from those reporting the patient did not tolerate the drug.

Does the density study matter?

It is frequently required and frequently stale. Where the policy sets an interval, a study outside it is a clean basis for denial, and supplying a current one is faster than arguing the interval.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →